SCHEMBL119065

SCHEMBL119065

CCCCCCC(CC)OC(=O)/C=C/c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.51
LMNA P02545 1/20 0.47
HDAC3 O15379 2/20 0.45
AKR1B10 O60218 1/20 0.45
AKR1B1 P15121 1/20 0.45
TUBB4A P04350 2/20 0.44
TUBB P07437 2/20 0.44
TUBA3C P0DPH7 2/20 0.44
TUBA1B P68363 2/20 0.44
TUBA4A P68366 2/20 0.44
TUBB4B P68371 2/20 0.44
TUBB3 Q13509 2/20 0.44
TUBB2A Q13885 2/20 0.44
TUBB8 Q3ZCM7 2/20 0.44
TUBA3E Q6PEY2 2/20 0.44
TUBA1A Q71U36 2/20 0.44
TUBA1C Q9BQE3 2/20 0.44
TUBB6 Q9BUF5 2/20 0.44
TUBB2B Q9BVA1 2/20 0.44
TUBB1 Q9H4B7 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3222440 0.99 EGFR (0.49) EGFRLMNAHDAC3AKR1B10AKR1B1
SCHEMBL3222436 0.99 EGFR (0.49) EGFRLMNAHDAC3AKR1B10AKR1B1
SCHEMBL22293390 0.89 LMNA (0.51) EGFRLMNAHDAC3AKR1B10AKR1B1
4-Methoxycinnamic Acid SCHEMBL21195188 0.89 TDP1 (0.55) LMNATDP1ALDH1A1MEN1KMT2A
SCHEMBL119067 0.87 EGFR (0.49) EGFRLMNAHDAC3AKR1B10AKR1B1
SCHEMBL119063 0.87 EGFR (0.49) EGFRLMNAHDAC3AKR1B10AKR1B1
SCHEMBL19137922 0.87 CA12 (0.57) AKR1B10AKR1B1TDP1HCAR2MAOB
SCHEMBL28564004 0.87 TDP1 (0.46) LMNAAKR1B10AKR1B1TDP1ALDH1A1
SCHEMBL22293370 0.86 LMNA (0.53) EGFRLMNAHDAC3AKR1B10AKR1B1
SCHEMBL28474356 0.86 EGFR (0.47) EGFRLMNAHDAC3AKR1B10AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4251125-A1 COMPOSITIONS AND METHODS FOR PREVENTING AND PROTECTING AGAINST DAMAGE IN CELLS AND TISSUES F3 Platform Biologics, Inc. (US) 2023-10-04 EP claimed
US-20230000735-A1 ANTI-WRINKLE COSMETIC COMPOSITION, COMPOSITION SYSTEM AND METHOD FOR COSMETIC SKIN TREATMENT Natura Cosméticos S.A. (BR) 2023-01-05 US claimed
US-11478409-B2 Anti-wrinkle cosmetic composition, composition system and method for cosmetic skin treatment NATURA COSMETICOS S.A. (BR) 2022-10-25 US claimed
WO-2022115360-A1 COMPOSITIONS AND METHODS FOR PREVENTING AND PROTECTING AGAINST DAMAGE IN CELLS AND TISSUES F3 PLATFORM BIOLOGICS, INC. (US) 2022-06-02 WO claimed
US-20200113795-A1 COSMETIC COMPOSITION AND PREPARATION METHOD THEREFOR AMOREPACIFIC CORPORATION (KR) 2020-04-16 US claimed
US-20190167540-A1 ANTI-WRINKLE COSMETIC COMPOSITION, COMPOSITION SYSTEM AND METHOD FOR COSMETIC SKIN TREATMENT Natura Cosméticos S.A. (BR) 2019-06-06 US claimed
EP-3466406-A1 ANTI-WRINKLE COSMETIC COMPOSITION, COMPOSITION SYSTEM AND METHOD FOR COSMETIC SKIN TREATMENT Natura Cosméticos S.A. (BR) 2019-04-10 EP claimed
US-8152860-B2 Cosmetic composition for coloring hair comprising a direct hair dye and a carrier system comprising polysaccharides ROVI COSMETICS INTERNATIONAL GMBH (DE) 2012-04-10 US claimed
WO-2009069933-A2 OIL-IN-WATER SOLID COSMETIC COMPOSITION WITH HIGHER STABILITY AGAINST EVAPORATION OF INTERNAL PHASE (WATER) AS WELL AS OUTSTANDING MOISTURIZING EFFECT AMOREPACIFIC CORPORATION (KR) 2009-06-04 WO claimed
EP-2040667-A1 MOISTURISING AND SUNSCREEN SKINCARE COMPOSITION Reckitt & Colman (Overseas) Limited (GB) 2009-04-01 EP claimed
WO-2007144670-A1 MOISTURISING AND SUNSCREEN SKINCARE COMPOSITION RECKITT & COLMAN (OVERSEAS) LIMITED (GB) 2007-12-21 WO claimed
US-7208142-B2 Indanylidene compounds SYMRISE GMBH & CO. KG (DE) 2007-04-24 US claimed
US-7147841-B2 Formulation of UV absorbers by incorporation in solid lipid nanoparticles CIBA SPECIALTY CHEMICALS CORPORATION (US) 2006-12-12 US claimed
EP-1378231-A1 Formulation of UV absorbers by incorporation in solid lipid nanoparticles Ciba Specialty Chemicals Holding Inc. (CH) 2004-01-07 EP claimed
US-20030235540-A1 Formulation of UV absorbers by incorporation in solid lipid nanoparticles CIBA SPECIALTY CHEMICALS CORP. 2003-12-25 US claimed
US-20020143203-A1 Novel indanylidene compounds SYMRISE GMBH & CO. KG (DE) 2002-10-03 US claimed
EP-3698770-B1 COSMETIC COMPOSITION FOR BLOCKING FINE DUST LG HOUSEHOLD & HEALTH CARE LTD (KR) 2024-09-11 EP disclosed
US-20240122948-A1 COMPOSITIONS AND METHODS FOR PREVENTING AND PROTECTING AGAINST DAMAGE IN CELLS AND TISSUES F3 PLATFORM BIOLOGICS, INC. 2024-04-18 US disclosed
WO-1999051220-A1 METHODS AND COMPOSITIONS FOR REDUCING UV-INDUCED INHIBITION OF COLLAGEN SYNTHESIS IN HUMAN SKIN THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1999-10-14 WO disclosed
WO-1998055075-A2 COMPOSITIONS AND METHODS FOR INHIBITING PHOTOAGING OF SKIN REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1998-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030235540-A1 Formulation of UV absorbers by incorporation in solid lipid nanoparticles CUTA, LIPC, AUP1 EGFR 2607/4885LMNA 770/4885HDAC3 2906/4885
US-20020143203-A1 Novel indanylidene compounds CUTA, NISCH, ERCC4 EGFR 1033/4885LMNA 518/4885HDAC3 591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.